Kuke Music Holding Limited to Hold Extraordinary General Meeting and Class Meeting on September 12, 2025
Globenewswire· 2025-08-25 20:20
Beijing, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kuke Music Holding Limited (“Kuke” or the “Company”) (NYSE: KUKE), a leading classical music service platform in China, today published a notice to announce that it will hold an extraordinary general meeting (the “EGM”) of shareholders (the “EGM Notice”) at 10:30 am, Beijing Time, on September 12, 2025 at 25-1, Beijing Music Industrial Park, Heizhuanghu Road, Chaoyang District, Beijing, 100020 People’s Republic of China (or after the Class B Meeting, as def ...
Meridian to Divest Flooring Business, Including Taylor Adhesives, Polycom, and Frontier Products, to Avery Dennison
Prnewswire· 2025-08-25 20:20
CHARLOTTE, N.C., Aug. 25, 2025 /PRNewswire/ -- Meridian announced today that it has entered into a definitive agreement to divest its Flooring Adhesives Division—including the Taylor Adhesives, Polycom, and Frontier Products brands—to Avery Dennison, a global leader in materials science and digital identification solutions.Upon closing, the Flooring Business will be integrated into Avery Dennison's Materials Group business, positioning the brands for accelerated innovation and expanded reach."This transacti ...
[NUTX] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Nutex Health Inc. Investors
GlobeNewswire News Room· 2025-08-25 20:19
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) securities during the period of August 8, 2024 through August 14, 2025, inclusive (“the Class Period”). If you suffered a loss on your Nutex investments, you have until October 21, 2025 to request lead plaintiff appointment. Follow the link below for more information: [CONTACT THE F ...
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
GlobeNewswire News Room· 2025-08-25 20:17
SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA’s rejection of its leading cancer drug, RP1. The lawsuit alleges that Replimune misled investors by overstating the drug’s trial data and failing to disclose critical regulatory risks. The filing, known as Jboor v. Replimune Group, Inc., et al., is on behalf of inve ...
Genco Shipping & Trading Limited to Participate in the Jefferies Industrials Conference
Globenewswire· 2025-08-25 20:15
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, announced today that John C. Wobensmith, Chief Executive Officer, Peter Allen, Chief Financial Officer, and Michael Orr, Vice President, Finance, are scheduled to present at the Jefferies Industrials Conference on Wednesday, September 3, 2025 at 2:10 pm Eastern Time. Genco management will also ...
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway
Globenewswire· 2025-08-25 20:15
Core Insights - Serina Therapeutics is advancing SER-252 (POZ-apomorphine) for advanced Parkinson's disease under the 505(b)(2) NDA pathway, with U.S. IND filing planned for Q4 2025 and patient dosing in Australia expected to start in the same quarter [1][4] Company Developments - The FDA's feedback supports the registrational study program for SER-252, indicating that the initial study may be part of a registrational trial program [2][4] - The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial designed to evaluate safety, tolerability, and pharmacokinetics of SER-252 versus placebo [5] Product Information - SER-252 is designed to provide continuous dopaminergic stimulation via subcutaneous injection, aiming to reduce motor fluctuations in advanced Parkinson's patients [6] - The POZ platform technology enhances drug delivery by providing greater control in drug loading and release rates, potentially improving the efficacy and safety profile of various therapeutic agents [7][8] Future Plans - Serina plans to initiate U.S. enrollment in Q1 2026 following IND clearance, with data from Australian patients contributing to the overall regulatory review package [4] - The company aims to advance a pipeline of POZ-enabled small molecules that may follow similar regulatory pathways [3]
Comstock Announces the Purchase of All Equipment for Industry Scale Facility
Globenewswire· 2025-08-25 20:15
Scheduled for Delivery in Q4 2025, the Northern Nevada Complex will be the Largest in the U.S.VIRGINIA CITY, Nev., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced that on August 15, 2025, immediately following the Company’s previously announced successful public equity offering, that it had immediately placed all of the purchase orders and paid deposits totaling $5.1 million toward the purchase of all of the equipment for its 100,000 ton p ...
Vertiv to Participate in Upcoming Investor Conferences
Prnewswire· 2025-08-25 20:15
COLUMBUS, Ohio, Aug. 25, 2025 /PRNewswire/ -- Vertiv Holdings Co (NYSE: VRT), a global leader in critical digital infrastructure, today announced it is participating in two upcoming investor conferences in September.Giordano Albertazzi, Chief Executive Officer, and David Fallon, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference in San Francisco, California on Tuesday, September 9, 2025 at 8:10 a.m. Pacific time (11:10 a.m. Eastern time).Bo ...
Battalion Oil Corporation Announces Acceptance of Compliance Plan by NYSE American
Globenewswire· 2025-08-25 20:15
Core Points - Battalion Oil Corporation has received confirmation from NYSE American regarding the acceptance of its compliance plan to regain listing standards, with a plan period extending until November 30, 2026 [1][2] - The company was previously notified of noncompliance with NYSE American listing standards and submitted a detailed plan in response, which was accepted on August 19, 2025 [2] - NYSE American staff will monitor the company's progress during the plan period, and failure to comply may lead to delisting procedures [3] Management Comments - The CEO of Battalion Oil Corporation expressed appreciation for the acceptance of the compliance plan and emphasized the company's commitment to restoring compliance and strengthening operations and financial position [4] - The management remains confident in the long-term strategy and aims to deliver value to shareholders, although there is no assurance of success within the plan period [4]
SoundThinking to Present at the 2025 Gateway Conference on September 4, 2025
Globenewswire· 2025-08-25 20:15
FREMONT, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, announced today that the Company will present at the 2025 Annual Gateway Conference, which is being held September 3-4, 2025, at the Four Seasons Hotel in San Francisco, CA. SoundThinking's management team will present on Thursday, September 4th at 11:00 a.m. Pacific Time (PT). The presentation will be webcast live and available for replay here. In addition to the presentation, ...